AAAAAA

   
Results: 1-25 | 26-26
Results: 1-25/26
CHEMOTHERAPY IMMEDIATELY FOLLOWING AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH ADVANCED BREAST-CANCER
Authors: RAHMAN Z KAVANAGH J CHAMPLIN R GILES R HANANIA E FU SQ ZU ZF MEHRA R HOLMES F KUDELKA A CLAXTON D VERSCHRAEGEN C GAJEWSKI J ANDREEFF M HEIMFELD S BERENSON R ELLERSON D CALVERT L MECHETNER E HOLZMAYER T DAYNE A HAMER J BACHIER C OSTROVE J PRZEPIORKA D BURTNESS B COTE R BAST R HORTOBAGYI G DEISSEROTH A
Citation: Z. Rahman et al., CHEMOTHERAPY IMMEDIATELY FOLLOWING AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH ADVANCED BREAST-CANCER, Clinical cancer research, 4(11), 1998, pp. 2717-2721
USE OF THE INTERNATIONAL PROGNOSTIC INDEX AND THE TUMOR SCORE TO DETECT POOR-RISK PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA -A STUDY OF 37 PREVIOUSLY UNTREATED PATIENTS
Authors: ROMAGUERA JE DIAZPAVON JR CARIAS L HAGEMEISTER FB MCLAUGHLIN P RODRIGUEZ MA SARRIS AH YOUNES A PRETI A BACHIER C LLERENA E CABANILLAS F
Citation: Je. Romaguera et al., USE OF THE INTERNATIONAL PROGNOSTIC INDEX AND THE TUMOR SCORE TO DETECT POOR-RISK PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA -A STUDY OF 37 PREVIOUSLY UNTREATED PATIENTS, Leukemia & lymphoma, 28(3-4), 1998, pp. 295-306
PEPTIDE-CONTAINING THE BCR OLIGOMERIZATION DOMAIN (AA-1-160) REVERSESTHE TRANSFORMED PHENOTYPE OF P210(BCR-ABL) POSITIVE 32D MYELOID-LEUKEMIA CELLS
Authors: GUO XYD CUILLEROT JM WANG T WU Y ARLINGHAUS R CLAXTON D BACHIER C GREENBERGER J COLOMBOWALA I DEISSEROTH AB
Citation: Xyd. Guo et al., PEPTIDE-CONTAINING THE BCR OLIGOMERIZATION DOMAIN (AA-1-160) REVERSESTHE TRANSFORMED PHENOTYPE OF P210(BCR-ABL) POSITIVE 32D MYELOID-LEUKEMIA CELLS, Oncogene, 17(7), 1998, pp. 825-833
EX-VIVO EXPANSION OF BONE-MARROW CELLS FOR HEMATOPOIETIC RECONSTITUTION FOLLOWING HIGH-DOSE CHEMOTHERAPY FOR BREAST-CANCER
Authors: BACHIER C GOKMEN E TEALE J LANZKRON S HOUGHAM M MENEGHETTI C NANEZ A HUERTA J CHILDS C FRANKLIN W DOUVILLE J WEBER S ARMSTRONG D LEMAISTRE CF
Citation: C. Bachier et al., EX-VIVO EXPANSION OF BONE-MARROW CELLS FOR HEMATOPOIETIC RECONSTITUTION FOLLOWING HIGH-DOSE CHEMOTHERAPY FOR BREAST-CANCER, Experimental hematology, 26(8), 1998, pp. 67-67
RISK-FACTORS, TREATMENT, AND OUTCOME OF CENTRAL-NERVOUS-SYSTEM RECURRENCE IN ADULTS WITH INTERMEDIATE-GRADE AND IMMUNOBLASTIC LYMPHOMA
Authors: VANBESIEN K HA CS MURPHY S MCLAUGHLIN P RODRIGUEZ A AMIN K FORMAN A ROMAGUERA J HAGEMEISTER F YOUNES A BACHIER C SARRIS A SOBOCINSKI KS COX JD CABANILLAS F
Citation: K. Vanbesien et al., RISK-FACTORS, TREATMENT, AND OUTCOME OF CENTRAL-NERVOUS-SYSTEM RECURRENCE IN ADULTS WITH INTERMEDIATE-GRADE AND IMMUNOBLASTIC LYMPHOMA, Blood, 91(4), 1998, pp. 1178-1184
PHASE-I STUDY OF FLUDARABINE AND PACLITAXEL FOR THE TREATMENT OF LOW-GRADE NON-HODGKINS-LYMPHOMA
Authors: YOUNES A RODRIGUEZ MA MCLAUGHLIN P NORTH L SARRIS AH PATE O HAGEMEISTER FB ROMAGUERA J PRETI A BACHIER C CABANILLAS F
Citation: A. Younes et al., PHASE-I STUDY OF FLUDARABINE AND PACLITAXEL FOR THE TREATMENT OF LOW-GRADE NON-HODGKINS-LYMPHOMA, Leukemia & lymphoma, 26(1-2), 1997, pp. 77-82
PACLITAXEL (TAXOL(R)) FOR THE TREATMENT OF LYMPHOMA
Authors: YOUNES A AYOUB JP SARRIS A NORTH L PATE O MCLAUGHLIN P RODRIGUEZ MA ROMAGUERA J HAGEMEISTER F BACHIER C PRETI A CABANILLAS F
Citation: A. Younes et al., PACLITAXEL (TAXOL(R)) FOR THE TREATMENT OF LYMPHOMA, Annals of oncology, 8, 1997, pp. 129-131
RESULTS OF MDR-1 VECTOR MODIFICATION TRIAL INDICATE THAT GRANULOCYTE MACROPHAGE COLONY-FORMING UNIT CELLS DO NOT CONTRIBUTE TO POSTTRANSPLANT HEMATOPOIETIC RECOVERY FOLLOWING INTENSIVE SYSTEMIC THERAPY (VOL 93, PG 15346, 1996)/
Authors: HANANIA EG GILES RE KAVANAGH J FU SQ ELLERSON D ZU Z WANG T SU Y KUDELKA A RAHMAN Z HOLMES F HORTOBAGYI G CLAXTON D BACHIER C THALL P CHENG S HESTER J OSTROVE JM BIRD RE CHANG A KORBLING M SEONG D COTE R HOLZMAYER T MECHETNER E HEIMFELD S BERENSON R BURTNESS B EDWARDS C BAST B ANDREEFF M CHAMPLIN R DEISSEROTH AB
Citation: Eg. Hanania et al., RESULTS OF MDR-1 VECTOR MODIFICATION TRIAL INDICATE THAT GRANULOCYTE MACROPHAGE COLONY-FORMING UNIT CELLS DO NOT CONTRIBUTE TO POSTTRANSPLANT HEMATOPOIETIC RECOVERY FOLLOWING INTENSIVE SYSTEMIC THERAPY (VOL 93, PG 15346, 1996)/, Proceedings of the National Academy of Sciences of the United Statesof America, 94(10), 1997, pp. 5495-5495
PACLITAXEL ACTIVITY FOR THE TREATMENT OF NON-HODGKINS-LYMPHOMA - FINAL REPORT OF A PHASE-II TRIAL
Authors: YOUNES A AYOUB JP SARRIS A HAGEMEISTER F NORTH L PATE O MCLAUGHLIN P RODRIGUEZ MA ROMAGUERA J KURZROCK R PRETI A BACHIER C SMITH T CABANILLAS F
Citation: A. Younes et al., PACLITAXEL ACTIVITY FOR THE TREATMENT OF NON-HODGKINS-LYMPHOMA - FINAL REPORT OF A PHASE-II TRIAL, British Journal of Haematology, 96(2), 1997, pp. 328-332
INCIDENCE OF GRAFT VS. HOST-DISEASE IN PATIENTS UNDERGOING ALLOGENEICPERIPHERAL-BLOOD STEM-CELL TRANSPLANTS OR BONE-MARROW TRANSPLANTS ON CYCLOSPORINE AND STEROID PROPHYLAXIS
Authors: LANZKRON S BACHIER C ALEXANDER L MENEGHETTI C NANEZ A BOTELLO J HUERTA J CHILDS C LEMAISTRE CF
Citation: S. Lanzkron et al., INCIDENCE OF GRAFT VS. HOST-DISEASE IN PATIENTS UNDERGOING ALLOGENEICPERIPHERAL-BLOOD STEM-CELL TRANSPLANTS OR BONE-MARROW TRANSPLANTS ON CYCLOSPORINE AND STEROID PROPHYLAXIS, Blood, 90(10), 1997, pp. 4499-4499
PHASE-II STUDY OF TAXOL IN COMBINATION WITH MITOXANTRONE AND IFOSFAMIDE (MINT) WITH CONSOLIDATION ESHAP FOR LYMPHOMAS
Authors: ROMAGUERA J HAGEMEISTER FB MCLAUGHLIN P RODRIGUEZ MA BACHIER C PRETI H SARRIS AH WEBER D YOUNES A CABANILLAS F
Citation: J. Romaguera et al., PHASE-II STUDY OF TAXOL IN COMBINATION WITH MITOXANTRONE AND IFOSFAMIDE (MINT) WITH CONSOLIDATION ESHAP FOR LYMPHOMAS, Blood, 90(10), 1997, pp. 835-835
EX-VIVO EXPANSION OF STEM-CELLS (SC) FOR HEMATOPOIETIC RECONSTITUTIONFOLLOWING HIGH-DOSE CHEMOTHERAPY (HDC) FOR BREAST-CANCER
Authors: BACHIER C LANZKRON S HOUGHAM M MENEGHETTI C NANEZ A BOTELLO J HUERTA J SLANHAM S CHILDS C MULLER TE ARMSTRONG RD WEBER S LEMAISTRE CF
Citation: C. Bachier et al., EX-VIVO EXPANSION OF STEM-CELLS (SC) FOR HEMATOPOIETIC RECONSTITUTIONFOLLOWING HIGH-DOSE CHEMOTHERAPY (HDC) FOR BREAST-CANCER, Blood, 90(10), 1997, pp. 1632-1632
B-CELL AND T-CELL OBTAINED FROM EX-VIVO EXPANDED BONE-MARROW (BM) MONONUCLEAR CELL (MNC) TRANSPLANT RECIPIENTS EXHIBIT IG-H AND TCRVB CDR3 REPERTOIRES SIMILAR TO THAT SEEN AFTER CONVENTIONAL HEMATOPOIETIC STEM-CELL TRANSPLANTATION
Authors: GOKMEN E RAAPHORST FM BACHIER C LEMAISTRE CF MULLER TE ARMSTRONG RD BOLDT DH TEALE JM
Citation: E. Gokmen et al., B-CELL AND T-CELL OBTAINED FROM EX-VIVO EXPANDED BONE-MARROW (BM) MONONUCLEAR CELL (MNC) TRANSPLANT RECIPIENTS EXHIBIT IG-H AND TCRVB CDR3 REPERTOIRES SIMILAR TO THAT SEEN AFTER CONVENTIONAL HEMATOPOIETIC STEM-CELL TRANSPLANTATION, Blood, 90(10), 1997, pp. 2403-2403
AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) IN PATIENTS WITH FOLLICULAR NON-HODGKINS-LYMPHOMAS (FNHL) USING CD34+ SELECTION AND RETROVIRAL HEMATOPOIETIC TRANSDUCTION
Authors: BACHIER C GILES RE ELLERSON D HANANIA EG GARCIASANCHEZ F HALEY T CABANILLAS F CHAMPLIN R BERENSON R HEIMFELD S DEISSEROTH AB
Citation: C. Bachier et al., AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) IN PATIENTS WITH FOLLICULAR NON-HODGKINS-LYMPHOMAS (FNHL) USING CD34+ SELECTION AND RETROVIRAL HEMATOPOIETIC TRANSDUCTION, Journal of investigative medicine, 44(3), 1996, pp. 279-279
AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR POOR-PROGNOSISLOW-GRADE LYMPHOMA
Authors: FREYTES CO VUKELJA S SALZMAN D TSAI T CALLANDER N GOKMEN E RODRIGUEZ T CASTRO J BOLDT D ROODMAN GD HILSENBECK S ADKINS D BACHIER C CRAIG F CLARE N WEISNER A LEMAISTRE CF
Citation: Co. Freytes et al., AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR POOR-PROGNOSISLOW-GRADE LYMPHOMA, Experimental hematology, 24(9), 1996, pp. 629-629
RESULTS OF MDR-1 VECTOR MODIFICATION TRIAL INDICATE THAT GRANULOCYTE MACROPHAGE COLONY-FORMING UNIT CELLS DO NOT CONTRIBUTE TO POSTTRANSPLANT HEMATOPOIETIC RECOVERY FOLLOWING INTENSIVE SYSTEMIC THERAPY/
Authors: HANANIA EG GILES RE KAVANAGH J ELLERSON D ZU Z WANG T SU Y KUDELKA A RAHMAN Z HOLMES F HORTOBAGYI G CLAXTON D BACHIER C THALL P CHENG S HESTER J OSTROVE JM BIRD RE CHANG A KORBLING M SEONG D COTE R HOLZMAYER T MECHETNER E HEIMFELD S BERENSON R BURTNESS B EDWARDS C BAST R ANDREEFF M CHAMPLIN R DEISSEROTH AB
Citation: Eg. Hanania et al., RESULTS OF MDR-1 VECTOR MODIFICATION TRIAL INDICATE THAT GRANULOCYTE MACROPHAGE COLONY-FORMING UNIT CELLS DO NOT CONTRIBUTE TO POSTTRANSPLANT HEMATOPOIETIC RECOVERY FOLLOWING INTENSIVE SYSTEMIC THERAPY/, Proceedings of the National Academy of Sciences of the United Statesof America, 93(26), 1996, pp. 15346-15351
PROLONGED CLINICAL REMISSION IN PATIENTS (PTS) WITH INFLAMMATORY BOWEL-DISEASE (IBD) AFTER HIGH-DOSE CHEMOTHERAPY (HDC) AND AUTOLOGOUS BLOOD STEM-CELL TRANSPLANTATION (ABSCT)
Authors: CASTRO J BENTCH HL SMITH L KALTER S BACHIER C MENEGHETTI C MOORE A OLIVERSEN S LEMAISTRE CF
Citation: J. Castro et al., PROLONGED CLINICAL REMISSION IN PATIENTS (PTS) WITH INFLAMMATORY BOWEL-DISEASE (IBD) AFTER HIGH-DOSE CHEMOTHERAPY (HDC) AND AUTOLOGOUS BLOOD STEM-CELL TRANSPLANTATION (ABSCT), Blood, 88(10), 1996, pp. 519-519
RETROVIRAL GENE MARKING TO IDENTIFY THE ORIGIN OF RELAPSE FOLLOWING AUTOLOGOUS CD34 POSITIVE BONE-MARROW (BM) AND PERIPHERAL-BLOOD (PB) TRANSPLANTATION IN FOLLICULAR NONHODGKINS LYMPHOMA (FNHL)
Authors: BACHIER C GILES RE ELLERSON D HANANIA EG GARCIASANCHEZ F HALEY T ANDREEFF M CABANILLAS F CHAMPLIN R BERENSON R HEIMFELD S DEISSEROTH AB
Citation: C. Bachier et al., RETROVIRAL GENE MARKING TO IDENTIFY THE ORIGIN OF RELAPSE FOLLOWING AUTOLOGOUS CD34 POSITIVE BONE-MARROW (BM) AND PERIPHERAL-BLOOD (PB) TRANSPLANTATION IN FOLLICULAR NONHODGKINS LYMPHOMA (FNHL), Blood, 88(10), 1996, pp. 1707-1707
HCVAD MTX-ARAC - A NEW EFFECTIVE REGIMEN FOR DIFFUSE AND NODULAR MANTLE CELL LYMPHOMA (MCL)/
Authors: ROMAGUERA J KHOURI I KANTARJIAN H TEROLCASTERA MJ RODRIGUEZ MA HAGEMEISTER FB MCLAUGHLIN P YOUNES A SARRIS A BACHIER C PRETI HA PUGH W GARCIACONDE J CHAMPLIN R CABANILLAS F
Citation: J. Romaguera et al., HCVAD MTX-ARAC - A NEW EFFECTIVE REGIMEN FOR DIFFUSE AND NODULAR MANTLE CELL LYMPHOMA (MCL)/, Blood, 88(10), 1996, pp. 2261-2261
THE PRETREATMENT SERUM BETA-2-MICROGLOBULIN (BETA(2)M) IS THE MOST IMPORTANT FEATURE PREDICTING FREEDOM FROM PROGRESSION (FFP) IN CLINICALLY STAGED (CS) I-II HODGKINS-DISEASE (HD) TREATED WITH NOVP AND EXTENDED FIELD RADIOTHERAPY
Authors: HAGEMEISTER FB MCLAUGHLIN P RODRIGUEZ MA COX JD HA CS ROMAGUERA JE SARRIS A YOUNES A BACHIER C PRETI A CABANILLAS F
Citation: Fb. Hagemeister et al., THE PRETREATMENT SERUM BETA-2-MICROGLOBULIN (BETA(2)M) IS THE MOST IMPORTANT FEATURE PREDICTING FREEDOM FROM PROGRESSION (FFP) IN CLINICALLY STAGED (CS) I-II HODGKINS-DISEASE (HD) TREATED WITH NOVP AND EXTENDED FIELD RADIOTHERAPY, Blood, 86(10), 1995, pp. 2108-2108
PRELIMINARY-RESULTS OF A PHASE-II TRIAL OF TOPOTECAN IN PATIENTS WITHRELAPSING LYMPHOMA
Authors: PRETI HA PLUNKETT W SARRIS AH YOUNES A HAGEMEISTER F RODRIGUEZ MA ROMAGUERA J MCLAUGHLIN P BACHIER C CABANILLAS F ANDERSON MD
Citation: Ha. Preti et al., PRELIMINARY-RESULTS OF A PHASE-II TRIAL OF TOPOTECAN IN PATIENTS WITHRELAPSING LYMPHOMA, Blood, 86(10), 1995, pp. 3268-3268
CRYOPRESERVED MATCHED RELATED DONOR MARROW ENGRAFTS PROMPTLY FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION
Authors: CASTRO J BACHIER C BOLDT DH FREYTES C HARRIS K ROODMAN D SALZMAN D TAMI J MENEGHETTI C SHERIDANLEOS N LEMAISTRE CF
Citation: J. Castro et al., CRYOPRESERVED MATCHED RELATED DONOR MARROW ENGRAFTS PROMPTLY FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION, Blood, 84(10), 1994, pp. 10000093-10000093
BONE-MARROW TRANSPLANTATION (BMT) FOR ADULT POOR-RISK HIGH-GRADE NON-HODGKINS-LYMPHOMA (HGNHL)
Authors: BACHIER C FREYTES CO SALZMAN D CASTRO J BOLDT D ROODMAN GD HARRIS K CRAIG F WIESNER A LEMAISTRE CF
Citation: C. Bachier et al., BONE-MARROW TRANSPLANTATION (BMT) FOR ADULT POOR-RISK HIGH-GRADE NON-HODGKINS-LYMPHOMA (HGNHL), Blood, 84(10), 1994, pp. 10000703-10000703
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL RESCUE IN RESISTANT OR RECURRENT LOW-GRADE LYMPHOMA
Authors: FREYTES CO BACHIER C SALZMAN D VUKELIA S CASTRO J BOLDT D ROODMAN GD CRAIG F HARRIS K TSAI T SHERIDANLEOS N HILSENBECK S TAMI J BURRELL L LEMAISTRE CF
Citation: Co. Freytes et al., HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL RESCUE IN RESISTANT OR RECURRENT LOW-GRADE LYMPHOMA, Blood, 84(10), 1994, pp. 10000709-10000709
CD34-CELL SELECTION AND IMMUNOMAGNETIC PURGING (IMP) TO REMOVE CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL) CELLS FROM BONE-MARROW (BM)( STEM)
Authors: BACHIER C CRAIG F ROODMAN GD
Citation: C. Bachier et al., CD34-CELL SELECTION AND IMMUNOMAGNETIC PURGING (IMP) TO REMOVE CHRONIC LYMPHOCYTIC-LEUKEMIA (CLL) CELLS FROM BONE-MARROW (BM)( STEM), Blood, 84(10), 1994, pp. 10000726-10000726
Risultati: 1-25 | 26-26